ReviewCellular microbiology2016
Cryptococcal therapies and drug targets: the old, the new and the promising.
Review in Cellular microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 102 citations in OpenAlex.
- Trial
- Trial
- Targeting ceramide synthases for the development of new antifungals.Structure (London, England : 1993) · 2025Article
- Invasive pulmonary cryptococcosis mimicking metastatic lung cancer: A case report and review of literature.World journal of clinical cases · 2025Article
- Article
- Lack of an atypical PDR transporter generates an immunogenicbioRxiv : the preprint server for biology · 2025Article
- Reconstruction and exploitation of a dedicated Genome-Scale Metabolic Model of the human pathogenbioRxiv : the preprint server for biology · 2025Article
- The Hidden Fortress: A Comprehensive Review of Fungal Biofilms with Emphasis onJournal of fungi (Basel, Switzerland) · 2025Review
- Thiazole Derivatives as Promising Candidates for Cryptococcosis Therapy.ACS infectious diseases · 2025Article
- Unveiling new features of the human pathogenComputational and structural biotechnology journal · 2025Article
- Brilacidin, a novel antifungal agent againstmBio · 2024Article
- Investigation of the influence of pH and temperature on melanization and survival under oxidative stress in Cryptococcus neoformans.Archives of microbiology · 2024Article
- Unleashing Fungicidal Forces: Exploring the Synergistic Power of Amphotericin B-Loaded Nanoparticles and Monoclonal Antibodies.Journal of fungi (Basel, Switzerland) · 2024Article
- The Microevolution of Antifungal Drug Resistance in Pathogenic Fungi.Microorganisms · 2023Review
- Proteasome inhibition as a therapeutic target for the fungal pathogenMicrobiology spectrum · 2023Article
- No Chance to Survive:Antibiotics (Basel, Switzerland) · 2023Article
- Antifungal activity of eumelanin-inspired indoylenepheyleneethynylene againstFrontiers in microbiology · 2023Article
- Article
- Article
- The Antidepressant Sertraline Induces the Formation of Supersized Lipid Droplets in the Human PathogenJournal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Half a century after the introduction of Amphotericin B the management of cryptococcosis remains unsatisfactory. The disease, caused primarily by the two fungal species Cryptococcus neoformans and Cryptococcus gattii, remains responsible for considerable morbidity and mortality despite standard medical care. Current therapeutic options are limited to Amphotericin B, azoles and 5-flucytosine. However, this organism has numerous well-characterized virulence mechanisms that are amenable to pharmacological interference and are thus potential therapeutic targets. Here, we discuss existing approved antifungal drugs, resistance mechanisms to these drugs and non-standard antifungal drugs that have potential in treatment of cryptococcosis, including immunomodulatory strategies that synergize with antifungal drugs, such as cytokine administration or monoclonal antibodies. Finally, we summarize attempts to target well-described virulence factors of Cryptococcus, the capsule or fungal melanin. This review emphasizes the pressing need for new therapeutic alternatives for cryptococcosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.